Use of relaxin treat diseases related to vasoconstriction
AssigneesRAS Medical, Inc., The University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School, University of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsKirk P. Conrad, Martyn Lewis, Elaine N. Unemori, Xinfan Huang, Carol A. Tozzi
Life of this patent
Estimating the term…
Abstract
The invention related to methods of treating disease related to vasoconstriction that is a major factor in hypertensive vascular diseases and vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is useful in treating a wide variety of diseases relating to vasoconstriction.
Claims17
A method of treating hypertension, comprising administering to a patient in need thereof a pharmaceutical formulation comprising pharmaceutically active relaxin in an amount effective to reduce hypertension.
A method of treating hypertension, comprising administering an injectable formulation comprising pharmaceutically active recombinant human relaxin to a patient in an amount in a range of from 0.1 to 500 μg/kg of patient body weight, and continuing the administration over a period of time to reduce hypertension in the patient.
A method of increasing renal function, comprising administering to a patient in need thereof a pharmaceutical formulation comprising pharmaceutically active relaxin in an amount effective to increase a factor associated with renal function.
A method of treating pulmonary hypertension, comprising administering to a patient in need thereof a pharmaceutical formulation comprising pharmaceutically active relaxin in an amount effective to reduce pulmonary hypertension.
Dependencies are inferred from the claim text.